Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart patients may ditch blood thinners after ablation, major trial investigates

NCT ID NCT06871228

Disease control Sponsor: Beijing Anzhen Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether people with atrial fibrillation (AF) can safely stop taking blood thinners after a successful heart ablation procedure. About 4,100 adults aged 18-80 who have been on blood thinners for at least 2 months after ablation and have no signs of AF recurrence will be randomly assigned to either stop or continue their medication. All participants will use smartwatches and regular heart monitors to catch any return of AF. The goal is to see if stopping blood thinners reduces bleeding risks without increasing the chance of stroke or death.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 4,100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Participants must meet all of the following criteria: 1. Age 18 to 80 years. 2. 60±15 to 365±15 days after atrial fibrillation/atrial flutter (AF/AFL) ablation. 3. CHA2DS2-VA score ≥2. 4. No history of stroke, transient ischemic attack (TIA), or systemic embolism. 5. Continuous use of a NOAC since AF/AFL ablation. 6. No documented atrial tachyarrhythmia recurrence since ablation. 7. No antiarrhythmic drug (AAD) use within the past 2 months. 8. Able and willing to provide written informed consent. 9. Able and willing to comply with study procedures and follow-up. Exclusion Criteria Participants will be excluded if any of the following criteria are present: 1. High risk of post-ablation recurrence (e.g. including premature atrial contraction burden \>3% on any ambulatory ECG/Holter recording). 2. Moderate-to-severe mitral stenosis (mitral valve area ≤2.0 cm²) or mechanical heart valve. 3. Increased bleeding risk, including any of the following: 1. Current ISTH major bleeding or clinically relevant non-major bleeding (CRNMB). 2. History of non-traumatic major bleeding (e.g., intracranial, intraocular, spinal, retroperitoneal, gastrointestinal, or intra-articular) unless the reversible cause has been permanently eliminated. 3. Unresolved intracranial aneurysm/vascular malformation, or active/unhealed gastric or duodenal ulcer. 4. General anesthesia surgery within the past 3 months. 5. Planned surgery within the next 3 months. 6. Known bleeding diathesis (e.g., hemophilia). 7. Uncontrolled hypertension (SBP \>180 mmHg and/or DBP \>110 mmHg). 8. Hemoglobin \<90 g/L or blood transfusion within 4 weeks prior to enrollment. 9. Platelet count \<50 × 10⁹/L. 10. End-stage kidney disease (eGFR \<15 mL/min/1.73 m²) or on dialysis. 11. Severe liver disease (e.g., esophageal variceal bleeding, ascites, hepatic encephalopathy, or jaundice). 12. Known intolerance to oral anticoagulants or contraindication to oral anticoagulation. 4. Any condition requiring continued oral anticoagulation (e.g., pulmonary embolism, deep vein thrombosis, hypertrophic cardiomyopathy, cardiac amyloidosis). 5. Conditions associated with high non-cardioembolic stroke risk, including carotid, vertebral, or intracranial arterial stenosis ≥70%. 6. Prior left atrial appendage (LAA) occlusion, surgical LAA excision/closure, or intraoperative confirmation of LAA electrical isolation. 7. Female participants who are pregnant or breastfeeding, or of childbearing potential not using effective contraception. 8. Life expectancy \<2 years. 9. Current participation in another interventional clinical trial. 10. Any condition that, in the investigator's judgment, would make the participant unsuitable for the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation (AF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation Hemorrhage Thromboembolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation (AF)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    22 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Anzhen Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100029, China

  • Chengdu Fifth People's Hospital

    NOT_YET_RECRUITING

    Chengdu, Sichuan, 611130, China

  • First Affiliated Hospital of Dalian Medical University

    NOT_YET_RECRUITING

    Dalian, Liaoning, 116023, China

  • Guangdong Provincial People's Hospital

    NOT_YET_RECRUITING

    Guangzhou, Guangdong, 510080, China

  • Henan Provincial Chest Hospital

    NOT_YET_RECRUITING

    Zhengzhou, Henan, 450003, China

  • Liaocheng Heart Hospital

    NOT_YET_RECRUITING

    Liaocheng, Shandong, 252299, China

  • Liaocheng People's Hospital

    NOT_YET_RECRUITING

    Liaocheng, Shandong, 252000, China

  • Luohe Central Hospital

    NOT_YET_RECRUITING

    Luohe, Henan, 462003, China

  • Ningbo No.2 Hospital

    NOT_YET_RECRUITING

    Ningbo, Zhejiang, 315000, China

  • Qilu Hospital of Shandong University

    NOT_YET_RECRUITING

    Jinan, Shandong, 250012, China

  • Shengjing Hospital Affiliated to China Medical University

    NOT_YET_RECRUITING

    Shenyang, Liaoning, 110004, China

  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

    NOT_YET_RECRUITING

    Hangzhou, Zhejiang, 310009, China

  • The Affiliated Hospital of Xuzhou Medical University

    NOT_YET_RECRUITING

    Xuzhou, Jiangsu, 221002, China

  • The First Affiliated Hospital of Anhui Medical University

    NOT_YET_RECRUITING

    Hefei, Anhui, 230022, China

  • The First Affiliated Hospital of Harbin Medical University

    NOT_YET_RECRUITING

    Harbin, Heilongjiang, 150001, China

  • The First Affiliated Hospital of Nanjing Medical University

    NOT_YET_RECRUITING

    Nanjing, Jiangsu, 210036, China

  • The First Affiliated Hospital of Zhejiang University School of Medicine

    NOT_YET_RECRUITING

    Hangzhou, Zhejiang, 310000, China

  • The First Hospital of Jilin University

    NOT_YET_RECRUITING

    Changchun, Jilin, 130021, China

  • The Second Affiliated Hospital of Harbin Medical University

    NOT_YET_RECRUITING

    Harbin, Heilongjiang, 150085, China

  • The Second Hospital of Hebei Medical University

    NOT_YET_RECRUITING

    Shijiazhuang, Hebei, 050000, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    NOT_YET_RECRUITING

    Wuhan, Hubei, 430030, China

  • Wuhan Asia Heart Hospital

    NOT_YET_RECRUITING

    Wuhan, Hubei, 430022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.